Frazier Life Sciences Management, L.P. DSGN — DESIGN THERAPEUTICS INC

Ownership history in Frazier Life Sciences Management, L.P.  ·  7 quarters on record

AI Ownership Summary

Frazier Life Sciences Management, L.P. reported DESIGN THERAPEUTICS INC (DSGN) in 7 quarterly 13F filings from 2024 Q2 through 2025 Q4. Peak portfolio weight reached 0.5% in 2024 Q4. The latest visible filing shows DSGN at 0.13% of the fund.

This page tracks quarterly shares, estimated market value, portfolio weight, filing dates, and disclosure-aligned stock prices directly from SEC EDGAR 13F filings.

What this DSGN ownership page tells you

This page is designed to answer the real investor question behind a 13F filing: how meaningful was Frazier Life Sciences Management, L.P.'s position in DESIGN THERAPEUTICS INC, and how did that conviction change over time? You can read the holding window, peak weight, latest reported size, disclosure timing, and quarter-by-quarter changes without piecing the story together from raw SEC rows.

Freshest filing
Latest Reported Filing
2025 Q4

DSGN was reported at 0.13% of portfolio in the most recent visible filing.

High-water mark
Peak Conviction
0.5% in 2024 Q4

Peak weight helps separate a token disclosure from a real conviction holding the fund genuinely cared about.

Time in book
Holding Window
2024 Q2 to 2025 Q4

Longer holding windows often tell a very different story from short-lived tactical trades or one-quarter experiments.

Decision context
Why It Matters
Position size beats headlines

Knowing that a fund owned a stock is useful. Knowing whether it was a 0.20% placeholder or a true high-conviction position is where the signal actually starts.

DSGN stock page Frazier Life Sciences Management, L.P. fund profile Frazier Life Sciences Management, L.P. full holdings
How Frazier Life Sciences Management, L.P. held DSGN — position size vs. price
% of Fund (quarterly)    DSGN price (quarter-end, indexed to 100)    SPY (indexed to 100)    QQQ (indexed to 100)
📋 Quarterly Holdings History 7 quarters  ▾
Quarter Action Sold % After 3M Timing Shares Change Chg % % of Fund Mkt Value Filed Price (Filed)
2025 Q4 REDUCED 73.3% +13.4% ❌ 521,000 -1,432,547 -73.3% 0.13% $4.9M 2026-02-14 (Est.) $10.07
2025 Q3 UNCHANGED — — — 1,953,547 — 0% 0.44% $14.7M 2025-11-14 $7.37
2025 Q2 UNCHANGED — — — 1,953,547 — 0% 0.26% $6.6M 2025-08-14 $5.16
2025 Q1 UNCHANGED — — — 1,953,547 — 0% 0.34% $7.5M 2025-05-15 $3.36
2024 Q4 ADDED — — — 1,953,547 +61,000 +3.2% 0.50% $12.1M 2025-02-18 $4.13
2024 Q3 ADDED — — — 1,892,547 +697,368 +58.3% 0.41% $10.2M 2024-11-15 $5.80
2024 Q2 INITIATED — — — 1,195,179 — — 0.19% $4.0M 2024-08-15 $4.29

🏢 Other funds also holding DSGN

As of 2026 Q1 — sorted by position size

SR ONE CAPITAL MANAGEMENT, LP 3Y 7.59% AlphaCentric Advisors LLC 3Y 0.23% Lynx1 Capital Management LP 3Y 0.2% Palumbo Wealth Management LLC 3Y 0.19% Informed Momentum Co LLC 3Y 7Y 0.1% KENNEDY CAPITAL MANAGEMENT LLC 3Y 7Y 0.06% CAZ INVESTMENTS LP 3Y 7Y 0.04% ALGERT GLOBAL LLC 3Y 7Y 0.03% China Universal Asset Management Co., Ltd. 3Y 0.03% MIRABELLA FINANCIAL SERVICES LLP 3Y 0.01%

FAQ About Frazier Life Sciences Management, L.P. and DSGN

These are the practical questions this page is built to answer before you even open the full history table.

How long has Frazier Life Sciences Management, L.P. reported owning DSGN?

Frazier Life Sciences Management, L.P. reported DSGN across 7 quarterly 13F filings, from 2024 Q2 through 2025 Q4.

What was the largest reported DSGN position in Frazier Life Sciences Management, L.P.'s portfolio?

The largest reported portfolio weight for DSGN was 0.50% in 2024 Q4.

What is the latest reported DSGN position on this page?

The most recent filing on this page is 2025 Q4, when Frazier Life Sciences Management, L.P. reported 521,000 shares, equal to 0.13% of portfolio, with an estimated market value of $4.9M.

What does the chart on this DSGN ownership page compare?

The chart compares Frazier Life Sciences Management, L.P.'s quarterly DSGN portfolio weight with the stock's indexed share price, so you can see whether the fund was building, trimming, or holding the position as price moved.

How well did Frazier Life Sciences Management, L.P. time their DSGN position?

Based on 13F filing dates vs. subsequent DSGN price moves, Frazier Life Sciences Management, L.P. correctly timed 1 out of 3 reported position changes (33%). The annualised alpha on DSGN relative to SPY over the holding period was +51.8%.

← Back to Frazier Life Sciences Management, L.P. Holdings